Urinary Tract Infection (Serratia marcescens)
Overview
Plain-Language Overview
Urinary Tract Infection (UTI) caused by Serratia marcescens is an infection that affects the urinary system, including the bladder and urethra. This condition occurs when the bacteria Serratia marcescens enter and multiply in the urinary tract, leading to symptoms such as painful urination, frequent urge to urinate, and lower abdominal discomfort. The infection can sometimes spread to the kidneys, causing more severe symptoms like fever and flank pain. It mainly affects the urinary tract, which is responsible for removing waste and excess fluids from the body. This type of UTI is less common but can be more difficult to treat due to the bacteria’s resistance to many antibiotics. Early recognition and diagnosis are important to prevent complications. The infection disrupts normal urinary function and can cause significant discomfort and health issues if untreated.
Clinical Definition
Urinary Tract Infection (UTI) caused by Serratia marcescens is a bacterial infection of the urinary tract characterized by colonization and invasion of the bladder, urethra, or kidneys by the gram-negative bacillus Serratia marcescens. This organism is a member of the Enterobacteriaceae family and is notable for its intrinsic resistance to multiple antibiotics, including beta-lactams and aminoglycosides, complicating treatment. The infection typically arises in patients with urinary catheters, structural abnormalities, or immunocompromised states. Clinically, it presents with dysuria, urinary frequency, urgency, and sometimes systemic signs such as fever and flank pain if pyelonephritis develops. The pathogenesis involves bacterial adherence to uroepithelial cells, biofilm formation, and evasion of host immune defenses. This infection is significant due to its association with healthcare settings and potential for causing complicated UTIs and sepsis.
Inciting Event
Insertion of a urinary catheter introduces Serratia marcescens into the urinary tract.
Urinary tract instrumentation such as surgery or cystoscopy disrupts mucosal barriers.
Colonization of hospital environment leads to patient exposure and infection.
Antibiotic therapy alters normal flora, allowing Serratia overgrowth.
Urinary stasis due to obstruction or retention facilitates bacterial proliferation.
Latency Period
Hours to days after catheter insertion or instrumentation, symptoms typically develop.
Symptom onset may be delayed in immunocompromised patients due to blunted inflammation.
Colonization can precede symptomatic infection by several days in hospitalized patients.
Recurrent infections may occur weeks after initial treatment failure or reinfection.
Biofilm-associated infections may have a more indolent course with delayed presentation.
Diagnostic Delay
Atypical presentation in elderly or immunosuppressed patients leads to missed diagnosis.
Misattribution of symptoms to catheter irritation or other comorbidities delays testing.
Initial empiric antibiotics may not cover Serratia, delaying culture-based diagnosis.
Low clinical suspicion for Serratia as a urinary pathogen in community settings.
Delayed urine culture results postpone targeted antimicrobial therapy.
Clinical Presentation
Signs & Symptoms
Dysuria, urgency, and frequency are hallmark lower urinary tract symptoms.
Suprapubic pain and discomfort during urination.
Fever and chills may indicate upper tract involvement or systemic infection.
Cloudy or foul-smelling urine due to bacterial infection.
History of Present Illness
Dysuria, frequency, and urgency develop progressively over hours to days.
Fever and chills may indicate upper tract involvement or systemic infection.
Suprapubic or flank pain suggests cystitis or pyelonephritis respectively.
Cloudy or malodorous urine is commonly reported by affected patients.
In catheterized patients, increased leakage or obstruction may be noted.
Past Medical History
History of urinary catheterization or instrumentation is common.
Previous urinary tract infections, especially with resistant organisms, increase risk.
Chronic kidney disease or urinary tract abnormalities predispose to infection.
Immunosuppressive conditions such as diabetes or malignancy are relevant.
Recent hospitalization or antibiotic exposure often precedes infection.
Family History
[]
Physical Exam Findings
Suprapubic tenderness on palpation indicating bladder inflammation.
Costovertebral angle tenderness suggesting upper urinary tract involvement.
Fever may be present in complicated or upper urinary tract infections.
Tachycardia and signs of systemic infection in severe cases.
Diagnostic Workup
Diagnostic Criteria
Diagnosis is established by a combination of clinical symptoms such as dysuria, frequency, and urgency, along with laboratory confirmation. The key diagnostic test is a urine culture demonstrating significant growth of Serratia marcescens (typically >10^5 CFU/mL) in a properly collected midstream urine sample. Urinalysis often shows pyuria and bacteriuria. Blood cultures may be indicated if systemic infection is suspected. Imaging studies are reserved for complicated cases to assess for obstruction or abscess.
Pathophysiology
Key Mechanisms
Adherence of Serratia marcescens to uroepithelial cells via fimbriae facilitates colonization.
Biofilm formation on urinary catheters or mucosal surfaces promotes persistence and antibiotic resistance.
Production of proteases and hemolysins damages urinary tract epithelium, enhancing invasion.
Intrinsic resistance to multiple antibiotics complicates eradication and promotes infection.
Ascending infection from the urethra to bladder and possibly kidneys causes localized inflammation.
| Involvement | Details |
|---|---|
| Organs | Bladder is the primary organ affected in lower urinary tract infection, presenting with dysuria and urgency. |
Kidneys can be involved in pyelonephritis if the infection ascends, causing flank pain and systemic symptoms. | |
| Tissues | Urothelium lines the urinary tract and serves as the initial site of bacterial adherence and immune activation in infection. |
Renal interstitium may become inflamed in upper urinary tract infections caused by Serratia marcescens. | |
| Cells | Neutrophils are the primary immune cells that infiltrate the urinary tract to phagocytose Serratia marcescens and release antimicrobial substances. |
Macrophages contribute to bacterial clearance and antigen presentation during the infection. | |
Urothelial cells act as a barrier and participate in immune signaling during urinary tract infection. | |
| Chemical Mediators | Interleukin-8 (IL-8) is released by infected urothelial cells to recruit neutrophils to the site of infection. |
Tumor necrosis factor-alpha (TNF-α) promotes inflammation and helps coordinate the immune response against Serratia marcescens. | |
Lipopolysaccharide (LPS) from the bacterial outer membrane triggers innate immune activation and cytokine release. |
Treatments
Pharmacological Treatments
Fluoroquinolones
- Mechanism:
Inhibit bacterial DNA gyrase and topoisomerase IV, preventing DNA replication in Serratia marcescens.
- Side effects:
Tendon rupture
QT prolongation
Gastrointestinal upset
- Clinical role:
First-line
Third-generation cephalosporins
- Mechanism:
Inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins, effective against Serratia marcescens.
- Side effects:
Allergic reactions
Diarrhea
Superinfection
- Clinical role:
First-line
Carbapenems
- Mechanism:
Broad-spectrum beta-lactam antibiotics that inhibit bacterial cell wall synthesis, reserved for resistant Serratia strains.
- Side effects:
Seizures
Allergic reactions
Gastrointestinal upset
- Clinical role:
Second-line
Aminoglycosides
- Mechanism:
Bind to 30S ribosomal subunit causing misreading of mRNA and inhibition of protein synthesis in Serratia marcescens.
- Side effects:
Nephrotoxicity
Ototoxicity
Neuromuscular blockade
- Clinical role:
Adjunctive
Non-pharmacological Treatments
Ensure adequate hydration to promote urinary flow and help clear infection.
Catheter removal or replacement if catheter-associated infection is suspected.
Urinary drainage procedures if obstruction or abscess formation occurs.
Prevention
Pharmacological Prevention
Prophylactic antibiotics in patients with recurrent UTIs or urinary catheters.
Targeted antimicrobial therapy guided by urine culture sensitivities to prevent resistance.
Non-pharmacological Prevention
Proper catheter care and timely removal to reduce infection risk.
Adequate hydration to promote urinary flow and bacterial clearance.
Avoidance of urinary tract instrumentation unless clinically necessary.
Good perineal hygiene to reduce bacterial colonization.
Outcome & Complications
Complications
Pyelonephritis with potential renal scarring or abscess formation.
Sepsis from bacteremia in severe infections.
Urethral strictures or chronic inflammation from recurrent infections.
Antibiotic resistance complicating treatment due to Serratia's intrinsic resistance mechanisms.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Urinary Tract Infection (Serratia marcescens) versus Escherichia coli Urinary Tract Infection
Urinary Tract Infection (Serratia marcescens) | Escherichia coli Urinary Tract Infection |
|---|---|
Gram-negative rod, non-lactose fermenting, produces red pigment (prodigiosin) | Gram-negative rod, lactose-fermenting, most common cause of community-acquired UTI |
Often nosocomial or associated with urinary catheterization and instrumentation | Typically community-acquired, often related to sexual activity or urinary catheterization |
Frequently resistant to multiple antibiotics, including beta-lactams and aminoglycosides | Usually sensitive to first-line antibiotics like nitrofurantoin or TMP-SMX |
Urinary Tract Infection (Serratia marcescens) versus Klebsiella pneumoniae Urinary Tract Infection
Urinary Tract Infection (Serratia marcescens) | Klebsiella pneumoniae Urinary Tract Infection |
|---|---|
Gram-negative rod, non-lactose fermenting, produces characteristic red pigment | Gram-negative rod, lactose-fermenting, mucoid capsule visible on culture |
Commonly hospital-acquired, especially in patients with indwelling catheters | Common in patients with diabetes or chronic illness, often hospital-acquired |
Often multidrug-resistant, requiring carbapenems or combination therapy | Often sensitive to cephalosporins unless ESBL-producing |
Urinary Tract Infection (Serratia marcescens) versus Pseudomonas aeruginosa Urinary Tract Infection
Urinary Tract Infection (Serratia marcescens) | Pseudomonas aeruginosa Urinary Tract Infection |
|---|---|
Gram-negative rod, oxidase-positive, produces red pigment (prodigiosin) | Gram-negative rod, oxidase-positive, produces blue-green pigment (pyocyanin) |
Common in hospitalized patients with urinary catheters or instrumentation | Common in immunocompromised hosts and patients with long-term catheterization |
Often resistant to multiple antibiotics, including antipseudomonal agents | Requires antipseudomonal antibiotics such as piperacillin-tazobactam or ciprofloxacin |
Urinary Tract Infection (Serratia marcescens) versus Candida albicans Urinary Tract Infection
Urinary Tract Infection (Serratia marcescens) | Candida albicans Urinary Tract Infection |
|---|---|
Gram-negative rod bacterium producing red pigment | Yeast with budding cells and pseudohyphae on microscopy |
Typically occurs in hospitalized patients with urinary catheters or instrumentation | Common in immunocompromised patients, diabetics, or those with prolonged antibiotic use |
Requires targeted antibiotic therapy based on susceptibility testing | Responds to antifungal agents such as fluconazole |